版本:
中国

BRIEF-Biopharmx advances BPX-01 2 pct upon achieving statistical significance for primary endpoint

June 1 Biopharmx Corp:

* Biopharmx advances bpx-01 2% upon achieving statistical significance for primary endpoint

* Biopharmx corp says data show bpx-01 is generally well tolerated

* Biopharmx corp says phase 2b study demonstrates 59% reduction in number of acne lesions using bpx-01 2% versus. 44% in vehicle

* Biopharmx corp - ‍phase 2b study demonstrates 59% reduction in number of acne lesions using bpx-01 2% versus. 44% in vehicle​

* Biopharmx corp says researchers also found that no subjects experienced serious treatment-related adverse side effects Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐